OBJECTIVES: To map the current treatment pathway and resource use in advanced/metastatic ALK+ non-small cell lung cancer (NSCLC) in Greece, and estimate the impact of adding ceritinib in the future treatment pathway. METHODS: An expert panel of 7 leading oncologists was convened in order to map the local treatment pathway and resource use for ALK+ NSCLC. Published sources provided unit costs from the perspective of the Social Insurance Fund (SIF). Direct medical costs were included in the analysis: pharmaceutical, medical and hospital care, lab and imaging tests, accompanying treatment, and management of AEs and brain metastases for all four lines of treatment. Cost base year was 2014. The analysis estimated treatment duration based on progression free survival (PFS) from published literature and controlled for estimated brain metastasis frequency by treatment. RESULTS: The current treatment pathway in Greece for the management of ALK+ NSCLC utilizes 1^st line chemotherapy followed by crizotinib, chemotherapy, and palliative care in 2^nd, 3^rd and 4^th lines of treatment, respectively. The most widely used 1^st line chemotherapeutic regimen is carboplatin or cisplatin plus pemetrexed (73% of patients); the most commonly used 3^rd line chemotherapeutic agent is docetaxel (83% of patients). The average per patient cost in the current treatment pathway was estimated at €67,672, based on a 20-month treatment duration adjusted for median PFS. The costs associated with future scenario 1 (crizotinib, ceritinib, chemotherapy, palliative care -treatment duration adjusted to 26 months) and future scenario 2 (chemotherapy, ceritinib, chemotherapy, palliative care –treatment duration adjusted to 29.3 months) were €93,113 and €105,609, respectively. All cost estimates assumed completion of all four lines of treatment and all treatment cycles in each line. CONCLUSIONS: Ceritinib in the 2^nd line treatment of ALK+ NSCLC leads to an increase in total health care costs due to improved survival which produces longer treatment duration.